138163-08-3

Basic information

• Product Name: 4-FORMYL-N-CBZ-PIPERIDINE
• Synonyms: 4-FORMYL-N-CBZ-PIPERIDINE;4-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;BUTTPARK 92\50-59;BENZYL 4-FORMYLTETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;N-CBZ-4-PIPERIDINYLCARBOXALDEHYDE;N-CBZ-4-FORMYLPIPERIDINE;Piperidine-4-carboxaldehyde, N-CBZ protected;Benzyl 4-formyltetrahydro-1(2H)-pyridinecarboxylate, 90+%
• CAS NO: 138163-08-3
• Molecular Formula: C₁₄H₁₇NO₃
• Molecular Weight: 247.29
• Product Categories: Carbonyl Compounds;Heterocycles
• Mol File: 138163-08-3.mol

Chemical Properties

• Boiling Point: 384.5 °C at 760 mmHg
• Flash Point: 186.3 °C
• Appearance: /
• Density: 1.221 g/cm³
• Vapor Pressure: 4.07E-06mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: -2.18±0.40(Predicted)
• CAS DataBase Reference: 4-FORMYL-N-CBZ-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FORMYL-N-CBZ-PIPERIDINE(138163-08-3)
• EPA Substance Registry System: 4-FORMYL-N-CBZ-PIPERIDINE(138163-08-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-24/25
• Hazardous Substances Data: 138163-08-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-FORMYL-N-CBZ-PIPERIDINE is used as a key synthetic building block for the development of pyrimidinyltetrahydropyridoindoles. These molecules have the potential to act as estrogen receptor degrading PROTACs (Proteolysis Targeting Chimeras), which are a new class of therapeutic agents designed to degrade specific proteins within cells. By targeting and degrading estrogen receptors, these PROTACs may offer novel treatment options for various hormone-related disorders and cancers.

InChI:InChI=1/C14H17NO3/c16-10-12-6-8-15(9-7-12)14(17)18-11-13-4-2-1-3-5-13/h1-5,10,12H,6-9,11H2

Upstream product

• 138163-07-2 piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-methyl ester 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 122860-33-7 benzyl 4-(hydroxymethyl)piperidine-N-carboxylate 
• 160809-38-1 1-benzyl 4-ethyl piperidine-1,4-dicarboxylate 
• 501-53-1 benzyl chloroformate 
• 498-94-2 isonipecotic acid 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 79-37-8 oxalyl dichloride 
• 87413-09-0 Dess-Martin periodane 
• 148148-48-5 4-(N-methoxy-N-methyl-carbamoyl)-piperidine-1-carboxylic acid benzyl ester 
• 6457-49-4 4-piperidinemethanol 
• 1126-09-6 4-carbethoxypiperidine 

Downstream Products

• 138163-09-4 benzyl 4-vinylpiperidine-1-carboxylate 
• 184289-85-8 benzyl spiro[indole-3,4'-piperidine]-1'-carboxylate 
• 189442-56-6 4-[1-hydroxy-5-(2-fluoropyridin-4-yl)-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid benzyl ester 
• 200801-90-7 4-[1-hydroxy-5-(2-methylthiopyrimidin-4-yl)-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid benzyl ester 
• 189333-18-4 3-oxo-9-azaspiro[5.5]undec-4-ene-9-carboxylic acid benzyl ester 
• 660432-91-7 6-[2-((N-benzyloxycarbonyl)-4-piperidyl)-5-phenyl-3H-imidazol-4-yl]-1-(propane-2-sulfonyl)-1H-benzimidazole-2-ylamine 
• 1013329-95-7 benzyl 4-(hydroxy(phenyl)methyl)piperidine-1-carboxylate 
• 952750-58-2 benzyl 4-({[4-(2-{[amino(imino)methyl]amino}-4-ethyl-1,3-thiazol-5-yl)phenyl]amino}methyl)piperidine-1-carboxylate 
• 1004527-61-0 4-(1-methyl-4-phenyl-1H-imidazol-5-yl)piperidine 
• 922504-27-6 4-benzoylpiperidine-1-carboxylic acid benzyl ester 
• 916976-36-8 4-benzhydrylidene-piperidine-1-carboxylic acid benzyl ester 
• 159634-47-6 Ibutamoren 
• 633312-74-0 C₂₆H₃₂N₄O₃ 
• 527693-82-9 3-[N-(benzyloxycarbonylpiperidin-4-yl)]propenoic acid 

Relevant articles and documents

Drastic fluorine effect: Complete reversal of the selectivity in the Au-catalyzed hydroalkoxylation reaction of fluorinated haloalkynes

The gold-catalyzed hydration reaction of haloalkynes is highly regioselective producing 2-halomethylketones as the sole products. Herein, we document a drastic fluorine effect where the reaction of 1-halo-3,3-difluoroalkynes as substrates leads to a complete reversal of selectivity and produces 3,3-difluoroesters as the unique products.

THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER

The present disclosure reports an extensive medicinal chemistry evaluation of a large collection of Truncating APC-Selective Inhibitor (TASIN) compounds. The compounds were evaluated for activity against a series of colon cancer cell lines with and withou

Highly regioselective gold-catalyzed formal hydration of propargylic: Gem -difluorides

Herein, we report a highly regioselective gold-catalyzed formal hydration of propargylic gem-difluorides. Not only does this transformation provide access to versatile fluorinated building blocks that were difficult or hardly possible to access beforehand, but it also represents a rare case of a highly regioselective gold-catalyzed hydroalkoxylation of internal alkynes and puts forward the utility of the difluoromethylene unit as a directing group in catalysis.

Ugi-type reactions of spirocyclic indolenines as a platform for compound library generation

A simple and efficient method for the synthesis of highly substituted spiroindoline derivatives is presented. A Fischer indolization is combined with Ugi-type reactions to explore the chemical space concerning this privileged structure. Moreover, spiropip

SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of Ρ2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.

INHIBITORS OF CYTOMEGALOVIRUS

Compounds of Formula (I) wherein R1, R2, R3A, R3B, Y, Z1 and Z2 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

A facile synthesis of the spiroindoline-based growth hormone secretagogue, MK-677

A facile and improved route for the synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677 was described. The key step adopted the Fischer indole/reduction strategy. The preparation of the key intermediates N-protected piperidine carboxaldehyde 5 and the N-Boc-O-benzyl-d-serine (2) are also optimized.

Substituted Disulfonamide Compounds

Substituted disulfonamide compounds corresponding to formula I: In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin receptor 1 (BR1).